1h Free Analyst Time
The Endometriosis Drugs Market grew from USD 2.54 billion in 2023 to USD 2.69 billion in 2024. It is expected to continue growing at a CAGR of 7.11%, reaching USD 4.11 billion by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
Endometriosis is a chronic condition often causing pain and infertility, affecting approximately 10% of reproductive-age women. The endometriosis drugs market focuses on pharmaceuticals designed to alleviate symptoms, slow disease progression, and improve quality of life. These medications commonly include hormonal therapies, nonsteroidal anti-inflammatory drugs (NSAIDs), and novel treatments like GnRH antagonists. The necessity of these drugs arises from the significant demand for effective non-surgical treatment options, as many patients require long-term management of their condition. Their application spans various healthcare settings, including hospitals, clinics, and at-home care, primarily aimed at symptom management and improving fertility outcomes. Key market drivers include increasing awareness and diagnosis rates, advancements in drug development, and a growing focus on developing personalized medicine approaches. Opportunities are prevalent in expanding therapeutic options beyond hormonal treatments, developing less invasive and more targeted therapies, and enhancing patient education and support programs. Despite these opportunities, significant challenges persist, including potential side effects of long-term drug use, high treatment costs, and the complexity of accurately diagnosing endometriosis. Moreover, reimbursement issues and lack of comprehensive understanding of the disease's pathophysiology add further hurdles. Innovation in this space could focus on developing novel drug delivery systems, biomarker discovery for early detection, and leveraging artificial intelligence for personalized treatment plans. The market remains competitive with key players investing in research and development to introduce improved therapeutics with better safety profiles. Collaborative efforts between pharmaceutical companies, healthcare providers, and patient advocacy groups are essential to overcome the barriers and enable widespread access to effective endometriosis management solutions. Understanding these dynamics is crucial for companies aiming to position themselves effectively in the market, emphasizing the need for continuous innovation and patient-focused care advancements.
Understanding Market Dynamics in the Endometriosis Drugs Market
The Endometriosis Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.- Market Drivers
- Government initiatives and support for women's health programs boosting endometriosis treatment availability
- Increasing availability and accessibility of minimally invasive treatments for endometriosis
- Rising patient awareness and advocacy for better endometriosis treatment options
- Expansion of telemedicine and digital health platforms facilitating endometriosis management
- Market Restraints
- Financial barriers and high costs associated with endometriosis treatment regimens
- Stigma and lack of awareness leading to delayed diagnosis and treatment in endometriosis patients
- Market Opportunities
- The application of nanotechnology for targeted drug delivery systems in endometriosis treatment
- The increasing investment in research and development for novel endometriosis therapeutics
- The expansion of healthcare policies to cover innovative endometriosis treatments and therapies
- Market Challenges
- Global regulatory compliance challenges affecting the market entry of new endometriosis treatments
- Supply chain disruptions leading to drug shortages and increased costs in endometriosis healthcare management
Exploring Porter’s Five Forces for the Endometriosis Drugs Market
Porter’s Five Forces framework further strengthens the insights of the Endometriosis Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.Applying PESTLE Analysis to the Endometriosis Drugs Market
External macro-environmental factors deeply influence the performance of the Endometriosis Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.Analyzing Market Share in the Endometriosis Drugs Market
The Endometriosis Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.Evaluating Vendor Success with the FPNV Positioning Matrix in the Endometriosis Drugs Market
The Endometriosis Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.Strategic Recommendations for Success in the Endometriosis Drugs Market
The Endometriosis Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.Key Company Profiles
The report delves into recent significant developments in the Endometriosis Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Allergan Plc, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Endo International Plc, Ferring Pharmaceuticals, GlaxoSmithKline Plc, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Myovant Sciences, Novartis AG, Organon & Co., Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Viatris Inc..Market Segmentation & Coverage
This research report categorizes the Endometriosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:- Drug Type
- Gonadotropins Releasing Hormone Agonists
- Nonsteroidal Anti-Inflammatory Drugs
- Oral Contraceptive Pills
- Progestin Therapy
- Route Of Administration
- Injectable
- Oral Drugs
- Patient Demographics
- Adult
- Geriatric
- Pediatric
- End-User
- Clinics
- Homecare Settings
- Hospitals
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report provides a detailed overview of the market, exploring several key areas:
- Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
- Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
- Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
- Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
- Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.
Additionally, the report addresses key questions to assist stakeholders in making informed decisions:
- What is the current size of the market, and how is it expected to grow?
- Which products, segments, and regions present the most attractive investment opportunities?
- What are the prevailing technology trends and regulatory factors influencing the market?
- How do top vendors rank regarding market share and competitive positioning?
- What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?
Table of Contents
1. Preface1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Government initiatives and support for women's health programs boosting endometriosis treatment availability
5.1.1.2. Increasing availability and accessibility of minimally invasive treatments for endometriosis
5.1.1.3. Rising patient awareness and advocacy for better endometriosis treatment options
5.1.1.4. Expansion of telemedicine and digital health platforms facilitating endometriosis management
5.1.2. Restraints
5.1.2.1. Financial barriers and high costs associated with endometriosis treatment regimens
5.1.2.2. Stigma and lack of awareness leading to delayed diagnosis and treatment in endometriosis patients
5.1.3. Opportunities
5.1.3.1. The application of nanotechnology for targeted drug delivery systems in endometriosis treatment
5.1.3.2. The increasing investment in research and development for novel endometriosis therapeutics
5.1.3.3. The expansion of healthcare policies to cover innovative endometriosis treatments and therapies
5.1.4. Challenges
5.1.4.1. Global regulatory compliance challenges affecting the market entry of new endometriosis treatments
5.1.4.2. Supply chain disruptions leading to drug shortages and increased costs in endometriosis healthcare management
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Endometriosis Drugs Market, by Drug Type
6.1. Introduction
6.2. Gonadotropins Releasing Hormone Agonists
6.3. Nonsteroidal Anti-Inflammatory Drugs
6.4. Oral Contraceptive Pills
6.5. Progestin Therapy
7. Endometriosis Drugs Market, by Route Of Administration
7.1. Introduction
7.2. Injectable
7.3. Oral Drugs
8. Endometriosis Drugs Market, by Patient Demographics
8.1. Introduction
8.2. Adult
8.3. Geriatric
8.4. Pediatric
9. Endometriosis Drugs Market, by End-User
9.1. Introduction
9.2. Clinics
9.3. Homecare Settings
9.4. Hospitals
10. Americas Endometriosis Drugs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Endometriosis Drugs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Endometriosis Drugs Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ENDOMETRIOSIS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ENDOMETRIOSIS DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ENDOMETRIOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. ENDOMETRIOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ENDOMETRIOSIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ENDOMETRIOSIS DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GONADOTROPINS RELEASING HORMONE AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVE PILLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PROGESTIN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ENDOMETRIOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 37. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 39. CANADA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 41. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 43. MEXICO ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 59. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 61. CHINA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. INDIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 63. INDIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. INDIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 65. INDIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 70. JAPAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 71. JAPAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. JAPAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 73. JAPAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. THAILAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 95. THAILAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. THAILAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 97. THAILAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 107. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 108. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 110. DENMARK ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 112. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 114. EGYPT ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 116. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 118. FINLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 120. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 122. FRANCE ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 124. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 126. GERMANY ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 132. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 134. ITALY ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 143. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 144. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 146. NORWAY ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. POLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 148. POLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. POLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 150. POLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 152. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 154. QATAR ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 167. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 168. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 170. SPAIN ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 180. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 182. TURKEY ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM ENDOMETRIOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. ENDOMETRIOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 192. ENDOMETRIOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
Companies Mentioned
The leading players in the Endometriosis Drugs Market, which are profiled in this report, include:- Abbott Laboratories
- AbbVie Inc.
- Allergan Plc
- AstraZeneca
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Endo International Plc
- Ferring Pharmaceuticals
- GlaxoSmithKline Plc
- Janssen Pharmaceuticals, Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- Myovant Sciences
- Novartis AG
- Organon & Co.
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Viatris Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 188 |
| Published | October 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 2.69 Billion |
| Forecasted Market Value ( USD | $ 4.11 Billion |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
